New product [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-03-11 15:40 (1672 d 16:15 ago) – Posting: # 21249
Views: 5,152

Dear SKM,

❝ Both the APIs are registered as individual products in market and we are just combining both. Why would you call it as a new product [...]



Because that's what it is. You have to distinguish API and formulation. This will be a new combination of two existing API.

By the way, if I'm not mistaken it would also be considered a "new drug" in India, according to the New Drugs and Clinical Trials Rules, 2019, Chapter 1, § 2 (1) (w) (iii): a fixed dose combination of two or more drugs, approved separately for certain claims and proposed to be combined for the first time in a fixed ratio, or where the ratio of ingredients in an approved combination is proposed to be changed with certain claims including indication, route of administration, dosage and dosage form.
—
Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,249 posts in 4,885 threads, 1,653 registered users;
76 visitors (0 registered, 76 guests [including 9 identified bots]).
Forum time: 08:56 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5